Alpha interferon: new associations in haematology/oncology. The Montpellier experience.
Haematology-Oncology Department, CHU Lapeyronie, Montpellier, France.
J F
JF
Rossi
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D005260:Female; D006402:Hematologic Diseases / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000276:immunology*; D007680:Kidney Neoplasms / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D015850:Interleukin-6